Serina Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Serina Therapeutics, Inc. (SER) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$6.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-13
- Serina Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$6.36M.
- Serina Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$6.90M.
- Serina Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$3.34M.
- Serina Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$4.59M, a 432.25% decline year-over-year.
- Serina Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$10.52M.
- Serina Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$8.69M.
- Serina Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$10.98M.
- Serina Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$12.38M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$6.36M 10-Q · filed 2026-08-13 | -$13.25M 10-Q · filed 2026-08-13 | -$16.59M derived: sum of 3 quarters · filed 2026-08-13 | -$21.18M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$6.90M 10-Q · filed 2026-08-13 | -$10.23M derived: sum of 2 quarters · filed 2026-08-13 | -$14.83M derived: sum of 3 quarters · filed 2026-08-13 | -$21.29M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$3.34M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-27 | -$7.93M derived: sum of 2 quarters · filed 2026-04-27 | -$14.39M derived: sum of 3 quarters · filed 2026-08-13 | -$19.21M DEF 14A · filed 2026-04-27 | ||||
| 2025-09-30 | -$4.59M 10-Q · filed 2025-11-13 | -$11.06M derived: sum of 2 quarters · filed 2026-08-13 | -$15.88M 10-Q · filed 2025-11-13 | -$18.63M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$6.46M 10-Q · filed 2026-08-13 | -$11.28M 10-Q · filed 2026-08-13 | -$14.04M derived: sum of 3 quarters · filed 2026-08-13 | -$12.65M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$4.82M 10-Q · filed 2026-08-13 | -$7.57M derived: sum of 2 quarters · filed 2026-08-13 | -$6.19M derived: sum of 3 quarters · filed 2026-08-13 | -$1.01M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2024-12-31 | -$2.75M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-27 | -$1.37M derived: sum of 2 quarters · filed 2026-04-27 | $3.81M derived: sum of 3 quarters · filed 2026-04-27 | -$11.21M DEF 14A · filed 2026-04-27 | ||||
| 2024-09-30 | $1.38M 10-Q · filed 2025-11-13 | $6.56M derived: sum of 2 quarters · filed 2025-11-13 | -$8.46M 10-Q · filed 2025-11-13 | -$7.40M derived: sum of 4 quarters · filed 2026-04-27 | ||||
| 2024-06-30 | $5.18M 10-Q · filed 2025-11-13 | -$9.84M 10-Q · filed 2025-08-11 | -$8.79M derived: sum of 3 quarters · filed 2026-04-27 | -$7.04M derived: sum of 4 quarters · filed 2026-04-27 | ||||
| 2024-03-31 | -$15.02M 10-Q · filed 2025-11-13 | -$13.96M derived: sum of 2 quarters · filed 2026-04-27 | -$12.21M derived: sum of 3 quarters · filed 2026-04-27 | -$11.40M derived: sum of 4 quarters · filed 2026-04-27 | ||||
| 2023-12-31 | $1.05M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-27 | $2.80M derived: sum of 2 quarters · filed 2026-04-27 | $3.61M derived: sum of 3 quarters · filed 2026-04-27 | $5.27M DEF 14A · filed 2026-04-27 | -$14.81M 10-K · filed 2024-03-22 | |||
| 2023-09-30 | $1.75M 10-Q · filed 2024-11-12 | -$5.39M 10-Q · filed 2023-11-14 | $2.56M derived: sum of 2 quarters · filed 2024-11-12 | $4.22M 10-Q · filed 2024-11-12 | -$11.35M 10-Q · filed 2023-11-14 | $1.46M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $808.00K 10-Q · filed 2024-11-12 | -$2.68M 10-Q · filed 2023-08-14 | $2.47M 10-Q · filed 2024-08-09 | -$5.96M 10-Q · filed 2023-08-14 | -$295.00K derived: sum of 3 quarters · filed 2024-11-12 | -$2.73M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $1.66M 10-Q · filed 2024-11-12 | -$3.29M 10-Q · filed 2023-05-12 | -$1.10M derived: sum of 2 quarters · filed 2024-11-12 | -$3.54M derived: sum of 3 quarters · filed 2024-11-12 | -$6.16M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2022-12-31 | -$2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -$5.20M derived: sum of 2 quarters · filed 2024-03-22 | -$7.82M derived: sum of 3 quarters · filed 2024-03-22 | -$10.52M 10-K · filed 2024-03-22 | ||||
| 2022-09-30 | -$2.44M 10-Q · filed 2023-11-14 | -$5.05M derived: sum of 2 quarters · filed 2023-11-14 | -$7.76M 10-Q · filed 2023-11-14 | -$9.92M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$2.62M 10-Q · filed 2023-08-14 | -$5.33M 10-Q · filed 2023-08-14 | -$7.48M derived: sum of 3 quarters · filed 2023-08-14 | -$9.44M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | -$2.71M 10-Q · filed 2023-05-12 | -$4.87M derived: sum of 2 quarters · filed 2023-05-12 | -$6.82M derived: sum of 3 quarters · filed 2023-05-12 | -$9.30M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | -$2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$4.11M derived: sum of 2 quarters · filed 2023-03-31 | -$6.59M derived: sum of 3 quarters · filed 2023-03-31 | -$8.69M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | -$1.96M 10-Q · filed 2022-11-10 | -$4.43M derived: sum of 2 quarters · filed 2022-11-10 | -$6.53M 10-Q · filed 2022-11-10 | -$8.98M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | -$2.48M 10-Q · filed 2022-08-12 | -$4.57M 10-Q · filed 2022-08-12 | -$7.03M derived: sum of 3 quarters · filed 2022-08-12 | -$9.59M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | -$2.10M 10-Q · filed 2022-05-13 | -$4.55M derived: sum of 2 quarters · filed 2022-05-13 | -$7.12M derived: sum of 3 quarters · filed 2022-05-13 | -$9.85M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | -$2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$5.02M derived: sum of 2 quarters · filed 2022-03-29 | -$7.75M derived: sum of 3 quarters · filed 2022-03-29 | -$10.98M 10-K · filed 2022-03-29 | ||||
| 2020-09-30 | -$2.56M 10-Q · filed 2021-11-12 | -$5.30M derived: sum of 2 quarters · filed 2021-11-12 | -$8.52M 10-Q · filed 2021-11-12 | -$11.26M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | -$2.73M 10-Q · filed 2021-08-13 | -$5.95M 10-Q · filed 2021-08-13 | -$8.69M derived: sum of 3 quarters · filed 2021-08-13 | -$11.97M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | -$3.22M 10-Q · filed 2021-05-17 | -$5.96M derived: sum of 2 quarters · filed 2021-05-17 | -$9.24M derived: sum of 3 quarters · filed 2021-05-17 | -$12.39M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | -$2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$6.02M derived: sum of 2 quarters · filed 2021-03-31 | -$9.17M derived: sum of 3 quarters · filed 2021-03-31 | -$12.38M 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | -$3.28M 10-Q · filed 2020-11-16 | -$6.43M derived: sum of 2 quarters · filed 2020-11-16 | -$9.64M 10-Q · filed 2020-11-16 | -$12.92M derived: sum of 4 quarters · filed 2020-11-16 | ||||
| 2019-06-30 | -$3.15M 10-Q · filed 2020-08-14 | -$6.37M 10-Q · filed 2020-08-14 | -$9.64M derived: sum of 3 quarters · filed 2020-08-14 | -$11.82M derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2019-03-31 | -$3.21M 10-Q · filed 2020-05-14 | -$6.49M derived: sum of 2 quarters · filed 2020-05-14 | -$8.67M derived: sum of 3 quarters · filed 2020-05-14 | -$10.62M derived: sum of 4 quarters · filed 2020-05-14 | ||||
| 2018-12-31 | -$3.27M derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-03-31 | -$5.46M derived: sum of 2 quarters · filed 2020-03-31 | -$7.41M derived: sum of 3 quarters · filed 2020-03-31 | -$7.73M 10-K/A · filed 2020-03-31 | ||||
| 2018-09-30 | -$2.19M 10-Q · filed 2019-11-14 | -$4.14M derived: sum of 2 quarters · filed 2019-11-14 | -$4.46M 10-Q · filed 2019-11-14 | |||||
| 2018-06-30 | -$1.95M 10-Q · filed 2019-08-14 | -$2.27M 10-Q · filed 2019-08-14 | ||||||
| 2018-03-31 | -$321.00K 10-Q · filed 2019-05-15 | |||||||
| 2017-12-31 | -$6.64M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |